GLP-1 medications in hospitalized patients

Close-up of a blue injection pen placed on a table next to a meal, with a plate of food blurred in the background, suggesting a connection between medication and dietary context.Incretin-based therapies (collectively referred to as “GLP-1s”), have rapidly become foundational therapies for type 2 diabetes and obesity.1,2 They also are approved for cardiometabolic risk reduction and obstructive sleep apnea in patients with overweight or obesity.3,4 Researchers are finding potential in GLP-1s for treating chronic kidney disease, metabolic-associated steatotic liver disease (MASLD), substance use disorders, neurological conditions and other medical issues.5 As use increases, hospitals are caring for a growing number of patients who have taken these medications. 

What is equally important is the impact GLP-1 therapies may have on nutrition intake, recovery, foodservice operations and outcomes during hospitalization. This is why nutrition intervention led by Registered Dietitian Nutritionists (RDNs) is becoming essential to high-quality, cost-effective care.6,7 Clinicia, Sodexo's clinical and patient nutrition brand, is centered on equipping RDNs to address these challenges with specialized expertise.

Impact of GLP-1s in the inpatient setting

GLP-1 medications work by reducing appetite and eating impulses and slowing gastric emptying. During acute illness, these effects are of concern at precisely the time patients need adequate energy and protein to heal. 

Reductions in intake, before and during hospitalization, may contribute to the following issues.8-12 

  • Inadequate energy and protein consumption
  • Dehydration
  • Micronutrient deficiencies
  • Delayed wound healing and functional recovery
  • Increased risk of malnutrition and skeletal muscle loss (sarcopenia)
  • Increased plate waste and inefficient food service utilization

Intentional weight loss does not eliminate nutrition risk

A common misconception is that intentional weight loss does not come with nutritional risk. In reality, malnutrition and sarcopenia can be evident even in patients with higher body weight and may become exacerbated during acute illness.13,14

Consistent nutrition screening and assessment are important, regardless of treatment intent or recent weight changes. Early identification of nutrition risk by RDNs allows teams to implement strategies for successful patient outcomes.

Predictable symptoms require proactive planning

Gastrointestinal effects associated with GLP-1s (early satiety, nausea, constipation, diarrhea and reduced hunger) are common but often transient. When anticipated, they can be managed effectively.7,15 

Operationally, this requires coordination across clinical nutrition, nursing, pharmacy and food service to ensure:

  • Flexible meal patterns (e.g., smaller, more frequent meals)
  • Emphasis on nutrient-dense, high-protein options
  • Hydration and symptom-supportive strategies
  • Increased food palatability and tolerance

When these needs are not anticipated, hospitals are more likely to see poor intake and delayed recovery.

Medication timing still matters — even when GLP-1s are held

Many GLP-1 medications have long half-lives. Even when held due to procedures or acute illness, appetite suppression and GI effects may persist.16 Nutrition risk does not resolve simply because the medication is paused.

For patients identified as at nutrition risk and followed by the RDN, this underscores the importance of anticipatory nutrition planning, rather than reactive intervention after intake has declined.

Discharge is a critical transition point 

Hospitalization represents a key opportunity to connect patients on GLP-1 medications to ongoing outpatient nutrition care. Post discharge support helps patients maintain nutrition adequacy, preserve lean mass and translate medication-assisted weight loss into durable health benefits.6,7

As clinical teams look beyond the prescription to guide patients in the GLP-1 era, health systems that incorporate outpatient RDN referrals into discharge workflows strengthen continuity of care and reduce downstream risk.

What this means for hospitals

GLP-1 medications are now mainstream. RDNs are uniquely positioned to address any inpatient implications of the medications. Health systems that integrate nutrition intentionally into care delivery are better positioned to manage complexity, reduce avoidable risk and support recovery.

This creates an opportunity to:

  • Position RDNs as essential contributors to medication-related risk management
  • Strengthen collaboration between nutrition, pharmacy, nursing and food service
  • Improve outcomes, reduce length of stay and support value-based care goals

Organizations with proactive nutrition support are more likely to deliver consistent, high-quality care in an increasingly complex clinical landscape. 

Advancing inpatient care for GLP-1–related nutrition risks

Discover how Clinicia equips RDNs with specialized expertise to help manage medication-related nutrition risks and support safer hospital outcomes.

Explore Clinicia

Read our latest stories

  1. American Diabetes Association Professional Practice Committee for Diabetes. 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S166-S182. doi:10.2337/dc26-S008
  2. Nadolsky K, Garvey WT, Agarwal M, et al. American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease - 2025 Update. Endocr Pract. 2025;31(11):1351-1394. doi:10.1016/j.eprac.2025.07.017
  3. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. US Food and Drug Administration (FDA). Published March 8, 2024. Accessed May 8, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
  4. FDA Approves First Medication for Obstructive Sleep Apnea. US Food and Drug Administration (FDA). Published December 20, 2024. Accessed May 8, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
  5. Sheth K, Kim S, Porterfield L, Virani SS, Wadhwani S, Vaughan EM. The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes. Curr Atheroscler Rep. 2025;27(1):76. Published 2025 Jul 30. doi:10.1007/s11883-025-01319-6
  6. Gigliotti L, Warshaw H, Evert A, et al. Incretin-Based Therapies and Lifestyle Interventions: The Evolving Role of Registered Dietitian Nutritionists in Obesity Care. J Acad Nutr Diet. 2025;125(3):408-421. doi:10.1016/j.jand.2024.10.023
  7. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. Am J Lifestyle Med. Published online May 30, 2025. doi:10.1177/15598276251344827
  8. Christensen S, Robinson K, Thomas S, Williams DR. Dietary intake by patients taking GLP1 and dual GIP/GLP1 receptor agonists: A narrative review and discussion of research needs. Obes Pillars. 2024;11:100121
  9. Gibbons C, Blundell J, Tetens Hoff S, et al. Effects of oral semaglutide on energy intake, appetite, and food preferences in type 2 diabetes. Diabetes Obes Metab. 2021;23(3):754765
  10. Sibal R, Balamurugan G, Langley J, Graham Y, Mahawar K. Macronutrient, micronutrient supplementation and monitoring for patients on GLP1 agonists. Nutrients. 2025;17(23):3659
  11. Obesity Pillars Expert Consensus Group. Nutritional and lifestyle supportive care recommendations for management of obesity with GLP1–based therapies. Obes Pillars. 2026;17:100228
  12. Scott Butsch W, Sulo S, Chang AT, et al. Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study. Obes Pillars. 2025;15:100186. Published 2025 Jun 10. doi:10.1016/j.obpill.2025.100186
  13. Bradley M, Melchor J, Carr R, Karjoo S. Obesity and malnutrition in children and adults: A clinical review. Obes Pillars. 2023;8:100087. Published 2023 Sep 7. doi:10.1016/j.obpill.2023.100087 
  14. Cristancho C, Mogensen KM, Robinson MK. Malnutrition in patients with obesity: An overview perspective. Nutr Clin Pract. 2024;39(6):1300-1316. doi:10.1002/ncp.11228
  15. Fitch A, Gigliotti L, Bays HE. Application of nutrition interventions with GLP1–based therapies: A narrative review of the challenges and solutions. Obes Pillars. 2025;16:100205
  16. Kindel TL, Wang AY, Wadhwa A, et al. Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period. Clin Gastroenterol Hepatol. 2025;23(12):2083-2085. doi:10.1016/j.cgh.2024.10.003